Inhalation Research Services receives revised order with increased payment from US pharma company
(Stockholm 18 October 2022) Inhalation Research Services (IRS) has received a revised order increasing the amount that it will be paid by a US pharma company. The original order, communicated on 18 July 2022, was for 136,000 Euro. This has now been raised to 151,000 Euro as additional steps within the research project have been contracted out to IRS by the client.
ISAB’s world-class expertise in inhalation, and its high-precision IPL (Isolated Perfused Lung) ex vivo method, were decisive in the client’s choice of IRS for research into a new repurposed drug being reformulated for administration via the lungs.
ISAB CEO Manoush Masarrat: “We are pleased with the confidence our client has shown in Inhalation Research Services and our technology.”
For more information about Inhalation Sciences, please contact:
Manoush Masarrat, CEO
E-mail: Manoush.masarrat@inhalation.se
Mobile: +46 (0)73 628 9153
About Inhalations Sciences Sweden AB (publ)
Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company’s patented lab instruments PreciseInhale® and DissolvIt® enable researchers in the pharma industry to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, and so our health, when being inhaled.
The information above was provided by Inhalation Sciences Sweden AB according to EU Market Abuse Regulations. The information was provided, through the above contact person, for publication on October 18, 2022.
Tags: